Potential anti-cancer treatment method wins Kaye Award

December 19, 2011

Jerusalem -- A strategy for inhibiting a protein that is associated with the spread of cancer has won for a Hebrew University of Jerusalem Ph.D. student in chemistry one of this year's Kaye Innovation Awards at the university.

The innovation developed by Yftah Tal-Gan, a student of Prof. Chaim Gilon and Prof. Alexander Levitzki at the Institute of Chemistry, focuses on the inhibition of Protein Kinase B (PKB, also called Akt). Since the activation of PKB is associated with cancer, selective inhibition of this protein becomes a promising strategy for targeted cancer therapy.

Tal-Gan's method is based on mimicking the interaction of PKB with other proteins with which it comes into contact. This he accomplished through the use of peptides. Since peptides are built from the same amino acid building blocks as proteins, the peptides can thus be used as protein "mimics." Peptides, however, lack important pharmacological properties, such as stability.

Through chemical engineering, Tal-Gan managed to convert an active peptide inhibitor of PKB, named PTR6154, into a stable peptide "mimic" (peptidomimetic) that combines biological activity with favorable pharmacological properties.

The peptide could be used as a potential anti-cancer treatment that would operate through inhibiting PKB from performing its role of inducing cancer cell survival and cell division. The outcome is that the cancer cells would become susceptible to death signals and therefore die (unlike untreated cancer cells that are not susceptible to death signals and therefore do not die). The peptidomimetic could also potentially be combined with specific anti-cancer drugs, thus further enhancing the efficacy of the treatment method.
-end-
The Kaye Awards were established in 1994 by Isaac Kaye of England, a prominent industrialist in the pharmaceutical industry, to encourage faculty, staff, and students of the university to develop innovative methods and inventions with good commercial potential which will benefit the university and society.

The Hebrew University of Jerusalem

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.